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Abstract
Dynorphin A (Dyn A) is an endogenous ligand for kappa (κ) opioid receptors. To restrict the
conformational mobility, we synthesized several cyclic Dyn A-(1-11)NH2 analogs on solid phase
utilizing ring-closing metathesis (RCM) between the side chains of allylglycine (AllGly) residues
incorporated in positions 2, 5 and/or 8. Cyclizations between the side chains of AllGly gave
reasonable yields (56–74%) of all of the desired cyclic peptides. Both the cis and trans isomers
were obtained for all of the cyclic peptides, with the ratio of cis to trans isomers depending on the
position and stereochemistry of the AllGly. Most of the cyclic Dyn A-(1-11)NH2 analogs
examined exhibit low nanomolar binding affinity for κ opioid receptors (Ki = 0.84–11 nM). In two
of the three cases the configuration of the double bond has a significant influence on the opioid
receptor affinity and agonist potency. All of the peptides inhibited adenylyl cyclase (AC) activity
in a concentration-dependent manner with full or close to full agonist activity. These potent Dyn A
analogs are the first ones cyclized by RCM.
Introduction
Potent clinically used narcotic analgesic agents, such as morphine and its analogs, mainly
act as mu (μ) opioid receptor agonists. However, their use is associated with serious side
effects, such as respiratory depression, physiological and psychological dependence, and
constipation.1 Therefore considerable effort has focused on the development of κ selective
opioid agonists, especially those acting in the periphery, as potential analgesics without the
side effects associated with morphine and other μ opioid receptor agonists.2, 3 Besides their
roles in analgesia, κ opioid receptor agonists may also have other therapeutic applications,
which include the treatment of cocaine dependence,4 as neuroprotective and anticonvulsant
agents,5 and the treatment of HIV-1 and HIV-1 related encephalopathy. 6, 7 Ligands for κ
opioid receptors are very useful for studying the functions of κ opioid receptors at the
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molecular level, which in turn could be very important in the development of new
therapeutic agents.
Dynorphin A (Dyn A, Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-Lys-Leu-Lys-Trp-Asp-
Asn-Gln), a heptadecapeptide first isolated from porcine pituitary,8 is an endogenous ligand
for κ opioid receptors and is thought to be involved in a variety of physiological functions.9
Dyn A has an identical N-terminal tetrapeptide sequence (the “message” sequence, Tyr-Gly-
Gly-Phe)10 as most other mammalian opioid peptides and a C-terminal sequence (the
“address” sequence)10 which is unique to Dyn A. Dyn A-(1-13) and Dyn A-(1-11) exhibit
similar κ opioid receptor activity to Dyn A, 10 and therefore these two shorter peptides have
often served as parent structures for structure-activity relationship (SAR) studies and for the
development of analogs with improved κ affinity, selectivity, potency, and/or altered
efficacy.
Like most linear peptides, Dyn A can adopt numerous conformations, and because of this,
the biologically active conformations are not yet clear.11–16 This inherent conformational
flexibility may be one of the reasons that Dyn A also exhibits significant affinity for μ and δ
opioid receptors, resulting in low selectivity for κ opioid receptors.
Conformational constraint by cyclization is one approach that can be used to restrict the
flexibility of peptides, and therefore is a valuable approach to study topographical
requirements of receptors.17–20 Cyclization of peptides can provide potent and selective
ligands for receptors when appropriate conformational constraints are incorporated,18
because a well-fit pre-organized conformation decreases the entropy penalty for receptor
binding.19 Furthermore, cyclic peptides are often more stable to peptidases,21–23 and
therefore they can have improved pharmacokinetic profiles and represent promising lead
compounds for further development.
Conformational constraint by cyclization has been successfully employed in the
development of several potent opioid peptides. Several cyclic Dyn A analogs have been
synthesized and evaluated for their biological activity.1, 19, 24–31 Our laboratory
previously reported several cyclic Dyn A analogs where either the “message” or “address”
sequence 10 was constrained. cyclo[D-Asp2,Dap5]Dyn A-(1-13)NH2 (Dap = 2,3-
diaminopropionic acid) exhibits high affinity for both κ and μ opioid receptors.29 cyclo[D-
Asp5,Dap8]Dyn A-(1-13)NH2 shows modest affinity for κ opioid receptors compared with
the linear peptide Dyn A-(1-13)NH2, but it shows increased selectivity for κ over μ and δ
opioid receptors compared to Dyn A-(1-13)NH2.31 Cyclic Dyn A analogs have also been
prepared by other research groups utilizing either disulfide25–28 or amide24, 30 bonds to
constrain the peptides.
We utilized ring-closing metathesis (RCM) in the design and synthesis of new cyclic Dyn A
analogs. RCM has emerged as a very useful method for making cyclic organic compounds
as well as cyclic peptides.32–35 Compared with peptides cyclized by amide or disulfide
bond formation, there are some advantages of using RCM. The resulting carbon-carbon
bond is more stable than a disulfide or an amide bond.34, 36 Furthermore, in contrast to
cyclization via amide or disulfide bond, side chain functionalities can be maintained by
appropriate choice of the amino acid side chains for cyclization by RCM. In addition,
cyclization by RCM can potentially stabilize different conformations of a peptide compared
to a disulfide or amide as a result of the geometry of the linkage, The C-S-S-C dihedral
angle for disulfide linkages is approximately ± 90°. While the amide bond in a lactam
linkage can potentially be either cis (0°) or trans (180°), the conformation of this bond for
secondary amides is predominantly trans, except in selected cases involving a small ring
that favor the cis conformation due to ring strain in the trans conformation. Also the two
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conformations of the amide bond cannot be isolated from one another. In contrast, in many
cases both the cis and trans isomers of the double bond are obtained from RCM and can
often be separated from one another by careful choice of chromatographic conditions (see
below). This permits the examination of the effect of a cis double bond on the biological
activity of the peptide compared to that of the trans isomer, a comparison that isn’t possible
with cyclization via a lactam.
The application of RCM to the cyclization of opioid peptides has been very limited. To date
there have been only three reports of RCM cyclic analogs of short opioid peptides, namely
pentapeptide enkephalin analogs and tetrapeptides related to dermorphin.37–39 These
analogs were cyclized between D-allylglycine (D-AllGly) in position 2 and D- or L-AllGly
in position 4 in the tetrapeptides or position 5 in the enkephalin derivatives. Some of these
cyclic analogs showed potent activity at μ and δ opioid receptors; as expected, the
enkephalin derivatives exhibited low affinity for κ opioid receptors (the receptor affinities of
the tetrapeptides were not reported). In contrast, there have been no reports of longer opioid
peptides (e.g. Dyn A analogs) cyclized through RCM., or of peptides that preferentially
interact with κ opioid receptors. Here we describe our results for incorporating a cyclic
constraint via RCM in the “address” (C-terminal) sequence as well as the “message” (N-
terminal) sequence of Dyn A-(1-11)NH2. and the effects of the double bond configuration
on opioid receptor affinity and potency.
Results and discussion
Analog design
Cyclic [2,5] and [5,8] Dyn A-(1-11)NH2 analogs (Figure 1) were chosen to evaluate RCM
for cyclizing Dyn A analogs and to examine the effects of these cyclizations on κ opioid
receptor affinity, selectivity, efficacy, and potency. Substitution of a D-amino acid in
position 2 for Gly in the linear peptides is well tolerated by κ opioid receptors; however, this
modification in Dyn A analogs can greatly increase μ receptor affinity, resulting in
compounds that are either nonselective or selective for μ opioid receptors.40 Substitution of
this position with an L-amino acid decreases binding affinity for all three types of opioid
receptors. However, the κ opioid receptor is more tolerant of the L-configuration at this
position than the other opioid receptors, and therefore the selectivity for κ opioid receptors
can be increased by substitution with an L-amino acid.40 Based on these observations, in the
[2,5] cyclic analogs (Figure 1) both L- and D-allylglycine (AllGly) were introduced in
position 2 to evaluate their effects on affinity, selectivity, potency, and efficacy at κ opioid
receptors. Leu5 in Dyn A is not important for opioid activity,41 and therefore this position
can be used for cyclization. Similarly, Leu5 and Ile8 were substituted with AllGly and then
cyclized by RCM to yield the [5,8] cyclic analogs (Figure 1). Cyclization by RCM maintains
the hydrophobic nature of these residues (Figure 1).
Synthesis
The peptides were synthesized by solid phase synthesis using Fmoc-protected (Fmoc = 9-
fluorenylmethoxycarbonyl) amino acids (Scheme 1). L/D-AllGly was incorporated in
appropriate positions in the linear precursor peptides, and upon completion of assembly of
the peptide chains, second generation Grubbs’ catalyst was used to cyclize the peptides on
the solid support. A mixture of dichloromethane (DCM) and N,N-dimethylformamide
(DMF) (4/1, v/v) was used as the solvent for the RCM reaction. The addition of a small
amount of DMF has several advantages; DMF is compatible with both the hydrophilic
peptide chain and resin and allows a higher temperature to be used for the reaction. The
position or stereochemistry of the AllGly residue did not have much influence on the yield
of the desired cyclic peptides. Cyclizations between the side chains of AllGly generally gave
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reasonable yields of the desired cyclic peptides (56–74%, Table 1). Both the cis and trans
isomers were obtained for all of the cyclic peptides, with the ratio of cis to trans isomers, as
determined by NMR, varying from approximately 1:1.1 to 1:2.3, depending on the position
and stereochemistry of the AllGly (Table 1).
Because the cis and trans isomers have very similar retention times (within 0.7 min) in the
standard high-performance liquid chromatography (HPLC) system (5–50% of MeCN with
0.1% TFA over 45 min at 1 mL/min, see Table 2), a very slow gradient (0.1% increase in
solvent B/min) was used for purification. The two isomers were successfully separated and
characterized by HPLC, electrospray ionization mass spectrometry (ESI-MS), and nuclear
magnetic resonance (NMR) of the purified fractions (Tables 2 and 3).
The NMR J-couplings and chemical shifts were used to distinguish between the cis and
trans isomers.42–44 The splitting patterns of the vinyl protons for the cis and trans isomers
are very different due to the different coupling constants to the adjacent methylene protons.
For the trans isomer, the coupling constants between the two vinyl protons (J12) are ~15 Hz,
while the coupling constants between the vinyl protons and their corresponding adjacent
methylene protons (J13, J14, J25 and J26) are around 7–8 Hz (Table 3). Because of the
coupling constants, generally five peaks (approximate ratio of 1:2:2:2:1) were observed in
the NMR spectra of the trans isomers (Figure 2). For the cis isomer, the coupling constants
between the two vinyl protons (J12) are ~10 Hz, while the coupling constants between the
vinyl protons and adjacent methylene protons are ~10 and 2 Hz. Because of the broad
linewidth, only three peaks were generally observed for the cis isomers in a ratio of 1:2:1
(Figure 2). The chemical shifts of the two vinyl protons in the cyclic peptides are between
5.0 and 5.5 ppm (Table 3). The two vinyl protons in the cis isomer are slightly more
shielded (upfield) than in the trans isomers (Figure 2 and Table 3).
Pharmacology
The cyclic peptides were evaluated for their binding affinity at κ, μ, and δ opioid receptors
using radioligand binding assays31 (Table 4). Except for compound 1, all of the cyclic Dyn
A analogs examined exhibit low nanomolar binding affinity for κ opioid receptors (Ki = 0.84
– 11 nM).
The [2,5] cyclizations involving an L-AllGly in position 2 decreased κ opioid receptor
affinity. The trans isomer of cyclo[Ala2(-CH=CH-)Ala5]Dyn A-(1-11)NH2 (2) exhibits
modest κ opioid receptor affinity (Ki = 9.5 nM) (Table 4).45 However, the cis isomer 1
exhibits 10-fold lower affinity for κ receptors than the trans isomer 2, presumably due to the
differences in the peptides’ conformations. Compared with Dyn A-(1-11)NH2, both isomers
1 and 2 exhibit much lower affinity for μ and δ receptors, resulting in higher κ opioid
receptor selectivity for these compounds than Dyn A-(1-11)NH2 (Table 4). The cis isomer
(1) has similar selectivity as the trans isomer (2), even though it shows about 10-fold lower
affinity for κ opioid receptors. Thus while substitution of an L-amino acid in position 2 in
the cyclic peptides decreases κ opioid receptor affinity compared with Dyn A-(1-11)NH2,
the selectivity towards the other opioid receptors (μ and δ) can be increased, as the latter
receptors are less tolerant of the introduction of an L-amino acid in position 2 compared to κ
opioid receptors.
In contrast, the [2,5] cyclizations involving a D-AllGly in position 2 are well tolerated by κ
opioid receptors. The two isomers of cyclo[D-Ala2(-CH=CH-)Ala5]Dyn A-(1-11)NH2 (3
and 4) exhibit high κ opioid receptor affinity (Ki = 0.84 and 1.33 nM for the cis and trans
isomers, respectively, Table 4). However, these two compounds also exhibit high affinity for
μ and δ opioid receptors, and therefore have minimal selectivity for κ over these opioid
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receptors. These results are similar to those found for cyclo[D-Asp2,Dap5]Dyn A-(1-13)NH2
and cyclo[D-Asp2,Dap5]Dyn A-(1-11)NH2.29, 46
Schiller and Hruby previously reported the synthesis of several tetrapeptide and enkephalin
analogs utilizing RCM.37–39 The two olefinic dicarba analogs of the enkephalin cyclic
peptide H-Tyr-c[D-Cys-Gly-Phe-L-Cys]NH2 exhibit nanomolar affinity for both μ (2.40 nM
and 0.616 nM for the cis and trans isomers, respectively) and δ (6.55 nM and 1.25 nM for
the cis and trans isomers, respectively) opioid receptors.38 As expected, these enkephalin
analogs exhibit low affinity for κ opioid receptors (200 nM and 57.6 nM for the cis and
trans isomers, respectively).38 The addition of the C-terminal residues of Dyn A-(1-11)NH2
substantially increases the affinity for κ opioid receptors, while maintaining the affinity for μ
opioid receptors and decreasing the affinity for δ opioid receptors. Interestingly, while the
two enkephalin isomers reported previously have different affinities for all three opioid
receptors, our two cyclic Dyn A isomers 3 and 4 exhibit very similar affinities for each of
the receptors.
The cyclizations in the “address” sequence of Dyn A involving two AllGly residues
substituted in positions 5 and 8 are also tolerated by κ opioid receptors. The κ opioid
receptor affinity of the trans isomer of cyclo[Ala5(-CH=CH-)Ala8]Dyn A-(1-11)NH2 (6)
(2.46 nM) is 5-fold lower than Dyn A-(1-11)NH2. However, this compound exhibits
significantly higher selectivity for κ over μ and δ receptors (15- and 187-fold, respectively,
Table 4) than the linear Dyn A-(1-11)NH2. Similar to the isomers 1 and 2 of cyclo[Ala2(-
CH=CH-)Ala5]Dyn A-(1-11)NH2, the cis isomer of cyclo[Ala5(-CH=CH-)Ala8]Dyn A-
(1-11)NH2 (5) shows significantly lower affinity (4.4-fold) for κ opioid receptors (Ki = 10.9
nM) than the trans isomer 6. However, the two isomers (5 and 6) exhibit similar selectivities
for κ vs μ and δ opioid receptors (Table 4).
The cyclic analogs were also examined for concentration-dependent inhibition of adenylyl
cyclase (AC) (Table 5).47 All of the compounds inhibit AC activity in a concentration-
dependent manner with similar efficacy (≥ 90%) to the reference agonist Dyn A-(1-13)NH2.
Thus the cyclizations have little or no effect on the efficacy of these Dyn A-(1-11)NH2
analogs. The potencies (EC50) of these cyclic analogs in the AC assays (Table 5) are well
correlated with their κ opioid receptor affinities. The two isomers of cyclo[D-Ala2(-
CH=CH-)Ala5]Dyn A-(1-11)NH2 (3 and 4) exhibit the highest potency with EC50 values
(0.80 and 0.47 nM, respectively, Table 5) comparable to that of the parent peptide Dyn A-
(1-11)NH2. These results are consistent with those reported for cyclo[D-Asp2,Dap5]Dyn A-
(1-11)NH2.46 For the two isomers of cyclo[Ala2(-CH=CH-)Ala5]Dyn A-(1-11)NH2 (1 and
2), where the configuration of position 2 is L instead of D, the potencies dropped
significantly (487- and 69-fold for 1 and 2, respectively) compared with Dyn A-(1-11)NH2.
Similar to the affinities for κ opioid receptors, the trans isomer (2) is about 7-fold more
potent than the cis isomer (1). The two isomers of cyclo[Ala5(-CH=CH-)Ala8]Dyn A-
(1-11)NH2 (5 and 6) show intermediate potency among these cyclic peptides, with the trans
isomer 6 being 2.8-fold more potent than the corresponding cis isomer 5.
Conclusions
Here we report the synthesis of the first Dyn A analogs cyclized by RCM and the first
peptides that preferentially interact with κ opioid receptors cyclized by this methodology.
Cyclizations in both the “message” and “address” sequences of Dyn A were explored to
prepare potent κ opioid receptor agonists. While cyclization by RCM has been introduced
into the “message” sequence in enkephalin analogs and tetrapeptides related to dermorphin,
37–39 this is the first application of this type of cyclization in the “address” sequence of an
opioid peptide. Cyclization by RCM has some advantages over traditional approaches such
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as amide or disulfide bond formation in these Dyn A analogs. The carbon-carbon double
bond in these peptides retains similar lipophilicity to the side chains of Leu and Ile found in
positions 5 and 8 in Dyn A. The positions and stereochemistry of the residues involved in
the cyclizations influenced the affinity and selectivity for κ opioid receptors. Both [2,5]
cyclic analogs with the D-configuration in position 2 (compounds 3 and 4) retain high
affinity for κ, μ, and δ receptors, indicating that the conformations which are adopted by
these two peptides are compatible with all three opioid receptor types. Thus, these two
peptides show minimal selectivity for κ over μ receptors and low selectivity for κ over δ
receptors. The [5,8] cyclic analogs (compounds 5 and 6) show intermediate affinity for κ
opioid receptors; however, their selectivity over the other opioid receptors is greater than
Dyn A-(1-11)NH2. The [2,5] cyclic analogs with the L-configuration in position 2 (1 and 2)
show the lowest affinity for κ opioid receptors; however, these two compounds also exhibit
higher selectivity for κ receptors compared with the parent peptide Dyn A-(1-11)NH2. In the
latter two cases the configuration of the double bond has a significant influence on the
opioid receptor affinity and agonist potency, likely due to the double bond configuration
affecting the conformation of the cyclic portion of the peptide. In both cases the peptides
containing the trans double bond exhibits higher κ opioid receptor affinity, selectivity and
agonist potency in the AC assay than the cis isomer. Similar to Dyn A, these cyclic Dyn A
analogs all exhibit concentration-dependent agonist activity (≥ 90% efficacy) at κ opioid
receptors with potencies well correlated with their affinities.
These analogs represent interesting lead compounds for further characterization of
conformation-activity relationships for Dyn A at κ opioid receptors. Further studies of these
and other Dyn A analogs cyclized by RCM are ongoing in our laboratory.
Experimental section
Materials
All standard Fmoc-protected amino acids were purchased from Bachem (King of Prussia,
PA), Calbiochem-Novabiochem (San Diego, CA), Applied Biosystems (Foster City, CA), or
Peptides International (Louisville, KY). Fmoc-AllGly-OH and Fmoc-D-AllGly-OH were
purchased from NeoMPS (San Diego, CA). Fmoc-PAL-PEG-PS (PAL-PEG-PS = Peptide
Amide Linker-poly(ethylene glycol)-polystyrene) resin was purchased from Applied
Biosystems. Benzotriazole-1-yloxytripyrrolidinophosphonium hexafluorophosphate
(PyBOP) was purchased from Calbiochem-Novabiochem. DCM, N,N-diisopropylethylamine
(DIEA), DMF, acetic acid, diethyl ether, acetonitrile, methanol, and trifluoroacetic acid
(TFA) were purchased from Fisher Scientific (Hampton, NH). 1-Hydroxybenzotriazole
(HOBt) and triisopropylsilane (TIPS) were purchased from Acros Chemical Co. (Pittsburgh,
PA). All other chemicals including phenol, piperidine, second generation Grubbs’ catalyst
and DMSO-d6 (dimethyl sulfoxide-d6) were purchased from Aldrich Chemical Co.
(Milwaukee, WI).
Synthesis of cyclic Dyn A analogs
The peptides were synthesized on the Fmoc-PAL-PEG-PS resin (300 mg, 0.19–0.21 mmol/
g) using a CS Bio automated peptide synthesizer, except for the couplings of Fmoc-AllGly-
OH and Fmoc-D-AllGly-OH, which were performed manually. The synthesis of the
peptides cyclo[Ala2(-CH=CH-)Ala5]Dyn A-(1-11)NH2 (1 and 2) is shown in Scheme 1 as an
example. The desired Fmoc-protected amino acids were coupled to the growing peptide
chain with PyBOP, HOBt, and DIEA (4/4/10 relative to the resin substitution) in DMF (2
mL) for 2 h.; for Fmoc-AllGly-OH and Fmoc-D-AllGly-OH 2 equiv were used for the
couplings (using 2, 2, and 5 equiv of PyBOP, HOBt, and DIEA relative to the resin,
respectively). The completion of the reactions was determined by the ninhydrin test.48
Fang et al. Page 6













Following the assemble of linear precursor, the resin was mixed with 40 mol% second-
generation Grubbs’ catalyst in DCM/DMF (4/1, v/v) under reflux conditions (60 °C) for 2 d
(Scheme 1). The resin was then washed with DCM (10 × 5 mL) to remove the catalyst.
Finally, the resin was washed with methanol and dried under vacuum. The crude cyclic
peptides were cleaved from the resin by treating with 5 mL Reagent B (88% TFA, 5%
phenol, 5% water, and 2% TIPS) for 2 h49 and the peptides isolated as described previously.
50
Analysis of cyclic Dyn A analogs
The crude peptides were analyzed by analytical reversed-phase HPLC to determine the
yields and ratios of the two isomers obtained from the RCM reaction. A linear gradient of 5–
50% MeCN containing 0.1% TFA over 45 minutes, at a flow rate of 1 mL/min, was used for
the analysis.
The crude peptides were purified by preparative reversed-phase HPLC using a linear
gradient of 5–23% aqueous MeCN containing 0.1% TFA over 3 h (0.1% MeCN/min), at a
flow rate of 20 mL/min. The purity of the final peptides was verified using two analytical
HPLC systems (Table 2). For analytical HPLC, a linear gradient of 5–50% solvent B
(solvent A, aqueous 0.1% TFA and solvent B, MeCN (system 1) or MeOH (system 2)
containing 0.1% TFA) over 45 minutes, at a flow rate of 1 mL/min, was used. The final
purity of all of the peptides by both methods was greater than 98%. Molecular weights of the
peptides (Table 2) were determined by ESI-MS (Waters, Q-TOF).
The configuration of the double bond of the cyclic RCM peptides was determined by NMR
analysis. 1H NMR spectra of these compounds (2–5 mg) were obtained at 25 °C in DMSO-
d6 on a Bruker AVANCE DRX-500 spectrometer (500.13 MHz proton frequency) equipped
with a 5 mm z-gradient Cryoprobe. 1H chemical shifts referenced to the residual DMSO
signal at 2.49 ppm and coupling constants were extracted from the 1D spectra (Table 3). The
1D 1H-NMR spectra of these cyclic analogs are provided in the supporting information.
Pharmacological assays
Radioligand binding assays were performed as previously described31 using cloned rat κ, rat
μ, and mouse δ opioid receptors stably expressed separately on CHO cells.
[3H]Diprenorphine (0.4 nM), [3H]DAMGO ([D-Ala2,MePhe4,glyol]enkephalin, 1 nM) and
[3H]DPDPE (cyclo[D-Pen2,D-Pen5]enkephalin, 0.15 nM) were used as radioligands in the
binding assays for κ, μ, and δ opioid receptors, respectively. Incubations were carried out in
triplicate with varying concentrations of peptides (0.1 nM to 10 μM) for 90 min at room
temperature in the presence of peptidase inhibitors (10 μM bestatin, 30 μM captopril, and 50
μM L-leucyl-L-leucine) and 3 mM Mg2+. Nonspecific binding was determined in the
presence of 10 μM unlabeled Dyn A-(1-13)NH2,, DAMGO or DPDPE for κ, μ and δ
receptors, respectively. IC50 values were determined by nonlinear regression analysis to fit a
logistic equation to the competition data using GraphPad Prism software (GraphPad
Software Co., San Diego, CA). Ki values were calculated from the IC50 values by the Cheng
and Prusoff equation,51 using KD values of 0.45, 0.49 and 1.76 nM for [3H]diprenorphine,
[3H]DAMGO and [3H]DPDPE, respectively. The results presented are the mean ± SEM
from at least three separate assays.
The peptides were also evaluated for their ability to inhibit the synthesis of cAMP by AC
using cloned rat κ opioid receptors stably expressed on CHO cells as previously described.
47 Cells were washed twice with free F12 medium and then incubated for 4 h in 1 mL of the
same media containing 12 μCi [3H]adenine. The cells were then incubated at 37 °C for 40
min in the presence of 50 μM forskolin, peptidase inhibitors (10 μM bestatin, 30 μM
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captopril, and 50 μM L-leucyl-L-leucine) and varying concentrations of the peptide ligand
(0.1–10,000 nM in 10-fold dilutions). Incubations were terminated by the addition of 30 μL
of stop solution (2% sodium dodecyl sulfate and 1.3 mM cyclic adenosine monophosphate
(cAMP) in water), followed by the addition of 100 μL of conc perchloric acid and 750 μL
water. [14C]cAMP (500 cpm in 50 μL) was added to each well to correct for recovery. After
transferring the contents of the wells to 1.5 mL centrifuge tubes, 12 M KOH was added to
neutralize the samples. The resulting precipitates were pelleted by centrifugation at 10,000g
for 10 minutes. cAMP in the supernatants was isolated by sequential chromatography over
BioRad AG-50W-X4 cation exchange resin and neutral alumina. The concentrations of
[3H]cAMP and [14C]cAMP in the eluants were determined simultaneously by scintillation
counting. Counts were corrected for crossover and recovery. The efficacies of the analogs
are expressed relative to the reference compound Dyn A-(1-13)NH2. The results presented
are the mean ± SEM from at least three separate assays.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Structural comparison of cyclo[L/D-Ala2(-CH=CH-)Ala5]Dyn A-(1-11)NH2 (1–4) and
cyclo[Ala5(-CH=CH-)Ala8]Dyn A-(1-11)NH2 (5, 6) with Dyn A-(1-11)NH2
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Chemical shifts and splitting patterns of the two vinyl protons of cyclic peptides 5 (a, cis)
and 6 (b, trans)
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Synthesis of cyclic peptides 1 and 2
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Table 1
Yields and cis/trans ratios of Dyn A(1-11)NH2 analogs cyclized by RCM
Entry Compounda Products (% by HPLC)b cis/transc
A cyclo[Ala2(-CH=CH-)Ala5]Dyn A-(1-11)NH2
cis, 1; trans, 2
56% 1:1.8
B cyclo[D-Ala2(-CH=CH-)Ala5]Dyn A-(1-11)NH2
cis, 3; trans, 4
74% 1:2.3
C cyclo[Ala5(-CH=CH-)Ala8] Dyn A-(1-11)NH2
cis, 5; trans, 6
63% 1:1.1
a
The alkene bridged cyclic constraints are designated as modifications to the side chains of alanine residues in the indicated positions. The
structures of the peptides are shown in Figure 2.
b
The remainder was the linear precursor peptide.
c
Configuration determined by NMR, see Table 3.
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Table 2
HPLC and ESI-MS data of purified peptides 1–6
Peptides HPLC tR (min)a ESI-MS (m/z)
System 1 System 2 Calculated Observed

































System 1: Solvent B = MeCN; system 2: Solvent B = MeOH; see the experimental section for details. The final purity of all of the peptides by
both methods was greater than 98%.
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Table 3
1H-NMR data for vinyl protons of cyclic peptides 1–6
Peptide Chemical shifts (δ) of vinyl protons J (Hz)
1 (cis) H1 = 5.10 J12 = 10.4
H2 = 5.34 J21 = 12.4
2 (trans) H1 = 5.25 J12 = 14.9
H2 = 5.47 J21 = 13.9
3 (cis) H1 = 5.05 J12 = 11.4
H2 = 5.16 J21 = 12.1
4 (trans) H1 = 5.12 J12 = 14.7
H2 = 5.26 J21 = 15.4
5 (cis) H1 = 5.14 J12 = 10.5
H2 = 5.41 J21 = 12.9
6 (trans) H1 = 5.21 J12 = 14.9
H2 = 5.46 J21 = 13.9
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Table 4
Opioid receptor binding affinities of Dyn A analogs cyclized by RCM
Compound Ki (nM) Ki ratio (κ/μ/δ)
κ μ δ
1 87.2 ± 6.9 763 ± 35 7670 ± 1030 1/8.8/88
2 9.46 ± 1.80 180 ± 10 1130 ± 98 1/19/119
3 0.84 ± 0.10 2.33 ± 0.20 9.30 ± 1.00 1/2.8/11
4 1.38 ± 0.31 2.33 ± 0.22 7.17 ± 0.55 1/1.7/5.2
5 10.9 ± 1.8 93.0 ± 6.0 1210 ± 90 1/8.5/111
6 2.46 ± 0.57 36.0 ± 2.1 460 ± 51 1/15/187
Dyn A-(1-11)NH2a 0.57 ± 0.01 1.85 ± 0.52 6.18 ± 1.01 1/3/11
a
From reference 45.
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Table 5
κ opioid receptor potencies and efficacies in the AC assay of Dyn A analogs cyclized by RCM
Compound EC50 (nM) Maximum AC % inhibitiona
1 190 ± 19 90 ± 2
2 27 ± 0.0 104 ± 4
3 0.80 ± 0.34 111 ± 6
4 0.47 ± 0.11 107 ± 4
5 23 ± 11 110 ± 10
6 8.3 ± 3.7 106 ± 6
Dyn A-(1-11)NH2 0.39 ±0.02 100
a
Relative to Dyn A-(1-11)NH2 (100%).
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